scholarly journals NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors

2021 ◽  
Vol 159 ◽  
pp. 113-124
Author(s):  
Carl M. Thielmann ◽  
Eleftheria Chorti ◽  
Johanna Matull ◽  
Rajmohan Murali ◽  
Anne Zaremba ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Tumour Origin

Clinical features, treatments and survival of HER2 positive gastric cancer with elevated alpha-fetoprotein: An analysis of 16 cases.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16000-e16000
Author(s):  
Shaohua Ge ◽  
Yi Ba ◽  
Ting Deng ◽  
Yuchong Yang ◽  
Tao Ning ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Elevated Serum ◽  
Her2 Positive ◽  
The Mean ◽  
Gastric Cancer Patients

e16000 Background: Gastric cancer with elevated alpha-fetoprotein (AFP) is a special type of gastric cancer with elevated serum AFP. It is often misdiagnosed as primary hepatic cancer due to abnormal AFP and liver metastasis. The AFP level is related to the prognosis of these patients in whom there is prone to high HER2 positive rate. Therefore, anti-HER2 treatment is optional, as well as the emerging immunotherapy with immune checkpoint inhibitors. Methods: Gastric cancer patients with HER2 and serum AFP examination were collected in our hospital from May 2017 till now. Serum AFP level over 7 ng/ml was defined as elevated AFP. The clinical characteristics, treatments and survival of the patients with HER2 positive and elevated AFP were picked and analyzed. Results: Among 135 gastric cancer patients with elevated AFP, 16 (11.9%) were HER-2 positive (12 with HER2 3+, 3 with HER2 2+/FISH+ and 1 with HER2 gene amplification in NGS). The mean serum AFP is 201.4± 476.7ng/ml (range: 7.74 -1335). There were 9 males and 7 females. The mean age was 55 years (range: 38-90). The tumors were located in stomach cardia and fundus in 5 cases, body in 5 cases, antrum in 4 cases, body and antrum in 1 case and whole stomach in 1 case. There were 2 patients in stage III and 14 patients in stage IV with metastasis to lymph node metastasis in 15, liver in 9, abdominal cavity in 3 and peritoneum in 3. As for the treatments, three patients underwent surgery, one of whom with exploratory laparotomy (no antitumor treatment after surgery, died from infection). In 13 advanced patients, 12 patients received systemic antitumor therapies (8 with chemotherapy+Trastuzumab+ immunotherapy, 2 with chemotherapy+Trastuzumab, 1 with chemotherapy+ immunotherapy and 1 with chemotherapy). The chemotherapy regimens were XELOX in 5 cases, SOX in 4 cases and FLOT in 2 cases. The response rate was 50% (6 in 12 patients) and the disease control rate was 100%. The median PFS was 7.5 months in first line therapy with six patients without progression disease yet. The longest PFS with PR lasted for 16.5 months with chemotherapy, trastuzumab and immune checkpoint inhibitor. Conclusions: Gastric cancer with HER2 positive and elevated serum AFP is a disease with special clinical characteristics. Patients with advanced diseases can be treated with chemotherapy, trastuzumab +/- immune checkpoint inhibitors. This combination is expected to become a new regimen to improve survival of such special patients.

Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors

2019 ◽  
Vol 115 (2) ◽  
pp. 251-261 ◽  
Author(s):  
Ethan D. Miller ◽  
Hamzah Abu-Sbeih ◽  
Brett Styskel ◽  
Graciela M. Nogueras Gonzalez ◽  
Boris Blechacz ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Adverse Impact

scholarly journals S0376 Clinical Characteristics and Outcome of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer

2020 ◽  
Vol 115 (1) ◽  
pp. S186-S186
Author(s):  
Jake Jacob ◽  
Barbara E. Dutra ◽  
Victor Garcia-Rodriguez ◽  
Kavea Panneerselvam ◽  
Fiyinfoluwa O. Abraham ◽  
...  
Keyword(s):  
Oral Mucositis ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Patients With Cancer

scholarly journals Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Yan Xiao ◽  
Lin Zeng ◽  
Qinglin Shen ◽  
Zhiyong Zhou ◽  
Zhifang Mao ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Inflammatory Arthritis ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Adverse Reactions ◽  
Checkpoint Inhibitors ◽  
Inflammatory Myopathy ◽  
Treatment Strategies ◽  
Multiple Organ ◽  
Diagnosis And Treatment

Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren’s syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE.

scholarly journals Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

2021 ◽  
Vol 27 (41) ◽  
pp. 7190-7206
Author(s):  
Kentaro Yamada ◽  
Tsunaki Sawada ◽  
Masanao Nakamura ◽  
Takeshi Yamamura ◽  
Keiko Maeda ◽  
...  
Keyword(s):  
Adverse Events ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

2020 ◽  
Author(s):  
Aljosja Rogiers ◽  
Carlo Tondini ◽  
Joe M. Grimes ◽  
Megan H. Trager ◽  
Sharon Nahm ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

scholarly journals Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors

2020 ◽  
Vol 78 (2) ◽  
pp. 276-280 ◽  
Author(s):  
Bernadett Szabados ◽  
Yasmin Abu-Ghanem ◽  
Michael Grant ◽  
Julia Choy ◽  
Axel Bex ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors
Sign in / Sign up

Export Citation Format

Share Document